Brefeldin AAlternative Names: BFA; NSC 89671
Latest Information Update: 28 May 2007
At a glance
- Originator Unknown
- Developer Braton Biotech; Nonindustrial source
- Class Cytostatic antibiotics; Macrolides
- Mechanism of Action Protein synthesis inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer; HIV infections; Inflammation